Johnson & Johnson Appoints Senior Leaders to Executive Committee

New Brunswick, NJ, December 9, 2021—Johnson & Johnson (NYSE: JNJ) (the Company) today announced the appointment of several senior leaders to the Company’s Executive Committee. Separately, the Company announced that Mr. Michael Sneed, Executive Vice President, Global Corporate Affairs and Chief Communication Officer, will be retiring on April 1, 2022.As previously announced, Mr. Alex Gorsky will serve as Executive Chairman of Johnson & Johnson and transition the Chief Executive Officer role to Mr. Joaquin Duato, currently Vice Chairman of the Company’s Executive Committee, effective January 3, 2022. From that time, all members of the Executive Committee will report to Mr. Duato. The new Executive Committee appointments are as follows: Ms. Vanessa Broadhurst, Company Group Chairman, Global Commercial Strategy Organization, has been appointed Executive Vice President, Global Corporate Affairs.Dr. Bill Hait, Global Head of Johnson & Johnson External Innovation, has been appointed Executive Vice President, Chief External Innovation, Medical Safety and Global Public Health Officer. Dr. Mathai Mammen, Global Head of R&D at the Janssen Pharmaceutical Companies of Johnson & Johnson, has been appointed Executive Vice President, Pharmaceuticals, R&D. Mr. James (Jim) Swanson, Chief Information Officer, has been appointed Executive Vice President, Chief Information Officer. Mr. Duato said, “I am thrilled to appoint this group of dynamic and experienced lead...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news